Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes-A Nationwide Cohort Study.

CONCLUSION: This study revealed that metformin use significantly reduced the risk of CRC in a dose-dependent manner in patients with type 2 DM in the Taiwanese population. However, a gradual decline in medication adherence may reduce the protective ability of metformin against CRC development during long-term therapy. PMID: 29524831 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29524831?dopt=Abstract

Source: Translational Oncology - March 7, 2018 Category: Cancer & Oncology Authors: Chang YT, Tsai HL, Kung YT, Yeh YS, Huang CW, Ma CJ, Chiu HC, Wang JY Tags: Transl Oncol Source Type: research